leadf
logo-loader
viewAldeyra Therapeutics

Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement

Dry eye treatment
The group said it now expects to initiate a phase 2b trial in the first half of 2018

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw its shares soar over 50% higher in premarket trade after the biotechnology company reported positive results from a phase 2a trial of its treatment for dry eye disease.

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement.

The group said it now expects to initiate a phase 2b trial in the first half of 2018.

Aldeyra’s chief executive Todd Brady said: “These data represent the fourth set of positive phase 2 results with ADX-102 in ocular inflammation.

"The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology."

In reaction to the news, Aldeyra shares were up 52.38%, putting them on track to open at the highest level seen in over nine months.

Quick facts: Aldeyra Therapeutics

Price: 13.22 USD

NASDAQ:ALDX
Market: NASDAQ
Market Cap: $513.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Condor Gold adds second drill rig as they look to ramp up drill program at...

Condor Gold (AIM: CNR- TSE: COG) CEO Mark Child joined Steve Darling from Proactive with news the company has added a second drill rig on their La India Project, in Nicaragua. Child telling Proactive, this rig will help speed up infill drilling on their current 4000-metre program. The...

9 hours, 6 minutes ago

2 min read